Alexandria Real Estate Equities has been named as a Top 10 Real Estate Investment Trust (REIT), according to Dividend Channel, which published its most recent ''DividendRank'' report. The report noted that among REITs, ARE shares displayed both attractive valuation metrics and strong profitability metrics. For example, the recent ARE share price of $80.91 represents a price-to-book ratio of 0.8 and an annual dividend yield of 6.53% — by comparison, the average stock in Dividend Channel's coverage universe y ...

Core Viewpoint - EPH European Property Holdings PLC expects a net profit of approximately EUR 4-5 million for the first half of 2025, a significant recovery from a net loss of EUR 13.89 million in the same period of 2024 [1][5] Financial Performance - The positive change in financial results is primarily attributed to a gain on revaluation of investment properties of approximately EUR 3 million, driven by a slight increase in market rental rates and stabilization of discount and capitalization rates at the end of 2024 [2] - In the first half of 2024, EPH recognized a loss of EUR 20 million on revaluation of investment properties due to rising capitalization and discount rates during that period [2] Revenue Streams - The revenue stream from rental properties remains stable, showing growth of approximately 3% compared to the first half of 2024, mainly due to rent indexations, high occupancy rates, and active asset management [3] - Loss from operations of the hotel property Trois Couronnes decreased from EUR 1.05 million in the first half of 2024 to EUR 0.63 million in the reporting period, with growth in all segments of hotel revenue, particularly from the newly opened restaurant [4]

Core Insights - ADP has introduced new AI-powered features aimed at addressing operational challenges in HR, particularly focusing on payroll errors, analytics, and administrative burdens [1][2][3] Group 1: AI Features and Benefits - The new features utilize ADP Assist to enhance efficiency in HR by tackling time-consuming tasks and improving accuracy in payroll processing [2][4] - Key functionalities include anomaly detection in payroll data, instant responses to HR inquiries, real-time visibility into workforce trends, compliance monitoring, and personalized employee development recommendations [6][7] Group 2: Client-Centered Approach - ADP's AI development is client-focused, with features tested rigorously based on client feedback, ensuring solutions are grounded in real-world complexities [5][6] - The company emphasizes a commitment to solving actual HR challenges rather than merely following industry trends, showcasing the practical application of AI to deliver measurable value [7] Group 3: Data and Market Reach - ADP's AI capabilities draw from extensive payroll and HR data insights, covering over 1.1 million companies across more than 140 countries, enabling informed decision-making for HR leaders [6][8] - The integration of AI across various HR functions provides a unified experience that evolves with user interactions while maintaining user control over critical decisions [7]

Euronext announces share repurchase programme as part of its long-term incentive plan         Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 3 September 2025 – Euronext today announced that it will repurchase 101,000 of its own shares as part of its Long-Term Incentive plans. This repurchase programme will be implemented and directed by an independent agent during the period commencing on 4 September 2025 (including) and ending no later than 6 October 2025 (including). This programme will be c ...

Euronext announces share repurchase programme as part of its long-term incentive plan Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 3 September 2025 – Euronext today announced that it will repurchase 101,000 of its own shares as part of its Long-Term Incentive plans. This repurchase programme will be implemented and directed by an independent agent during the period commencing on 4 September 2025 (including) and ending no later than 6 October 2025 (including). This programme will be carried ...

Question-and-Answer SessionJohn MoriciCFO & Executive VP of Global Finance Well, the majority of the discussions were just on kind of how the quarter played out and what our expectations were versus what actually happened. I mean on a typical basis, you go from first quarter to second quarter, you see a sequential improvement in terms of volume. Most of the Western World, you have teens that go into treatment over that time period. You see some of that growth that you would expect to -- as they get into tha ...

Presentation Ronald JoseyMD and Co-Head of Tech & Communications All right. I think we are on the clock, so we can get started here. I'm Ron Josey, I cover the Internet sector here at Citi. And look, I'm thrilled to have with us today, Ewout Steenbergen. Ewout, you joined about 1.5 years ago. We have a lot to get -- to talk to. Everybody here pretty much I'm sure you know what Booking.com does. So why don't we just jump into it? Thank you for joining us today. Ewout SteenbergenExecutive VP & CFO Happy t ...

PresentationAsiya MerchantVP & Analyst Here because we're always running short on time. It's busy. It's day 1 of our Global TMT conference. It feels like the afternoon already. But -- really pleased here to have Irving and Kris, both -- as well as WDC's IR, who are here in the audience. This is expected to be an open fireside. So we have some questions. But before we kick things off, I'd like to hand it over to WDC first for some prepared commentary, and then we can kick it off with some questions. So welco ...

Core Insights - Immunovant, Inc. presented six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients, indicating potential disease modification and strong durability of response [1][2][3] Study Details - The proof-of-concept study involved a 24-week treatment with batoclimab, followed by a 24-week off-treatment follow-up, focusing on patients with active Graves' disease [3][4] - The key endpoint was the normalization of free triiodothyronine (T3) and free thyroxine (T4) levels without increasing anti-thyroid drug (ATD) doses from baseline [3] Remission Data - Out of 21 patients in the follow-up period, approximately 80% (17/21) maintained normal thyroid function at the end of six months [6][7] - Among the responders, about 50% (8/17) achieved ATD-free remission, while an additional 30% (5/17) were on low ATD doses [6][7] Future Trials - Two potentially registrational trials for Immunovant's lead compound IMVT-1402 in Graves' disease are currently enrolling, with topline readouts expected in 2027 [5][6]

PresentationRyan KruegerManaging Director of Equity Research I'm Ryan Krueger, Life Insurance Analyst at KBW. It's great to have MetLife back with us again this year. Up on stage with me to my immediate right is Michel Khalaf, President and CEO, to the far right is John McCallion, CFO and Head of MetLife Investment Management. Also want to acknowledge John Hall, Treasurer and Head of Investor Relations; and other members of the IR team in the front row. So with that, Michel you launched a new 5-year strateg ...